Why the study?
Despite advances in management and therapies, valvular heart disease lacks adequate public and policymaker attention, with ongoing deficiencies in detection, systematic care, and treatment in health care systems such as China.
Implementation of a whole-life cycle management system may address current deficiencies in the care of patients with valvular heart disease, particularly in China.
Answers are grounded in this paper and cite their sources.
May address VHD care gaps in China via whole-life cycle management; leaves open impact on outcomes pending prospective trials.
Valvular heart disease (VHD) is rapidly increasing in prevalence worldwide, affecting millions and significantly impacting global health care systems. Despite notable advancements in understanding VHD progression, perioperative management, imaging techniques, and transcatheter therapies over the past 2 decades, the condition has not received the attention it deserves from the public and policymakers. Many patients with VHD in low- and middle-income countries continue to experience low detection, intervention, and follow-up rates. Systematic care for elderly patients and those with severe comorbidities, as well as postoperative patients, remains insufficient, leading to higher mortality and morbidity rates. This review focuses on the deficiencies in VHD treatment within the Chinese health care system and discusses the modern management program, known as the whole-life cycle management system, that has been implemented to enhance the survival prognosis of VHD patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: